Jaquelina Sonoe Ota Arakaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaquelina Sonoe Ota Arakaki has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Rudolf K. F. Oliveira
Division of Respiratory Diseases, Department of Medicine, Hospital São Paulo, Federal University of São Paulo (UNIFESP), São Paulo 04024-002, SP, Brazil
13 shared publications Roberta P. Ramos
Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
11 shared publications- Roberta Pulcheri Ramos
Federal University of São Paulo
10 shared publications - Eloara Vieira Machado Ferreira
Division of Respiratory Diseases, Department of Medicine Federal University of Sao Paulo Sao Paulo Brazil
7 shared publications Luiz E. Nery
Postgraduate Program in Pulmonary Medicine and Pulmonary Vascular Group, Division of Respiratory Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
7 shared publicationsEloara V.M. Ferreira
Division of Respiratory Diseases, Department of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil
6 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Estenose traqueal pós intubação: análise de 250 casos operados e o legado do professor Vicente Forte
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Open AccessEstenose traqueal pós intubação: análise de 250 casos operados e o legado do professor Vicente Forte
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Post-Intubation Tracheal Stenosis: Analysis of 250 Operated Cases and the Legacy of Professor Vicente Forte
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 53
Open AccessPost-Intubation Tracheal Stenosis: Analysis of 250 Operated Cases and the Legacy of Professor Vicente Forte
- Open Access
- 11 December 2025
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 51 (6) , e20250065
Diagnosis of pulmonary arterial hypertension: a statement from the Brazilian Thoracic Association
Pulmonary arterial hypertension (PAH) is a condition that predominantly affects the pulmonary arterial bed, leading to pulmonary vascular remodeling, progressive decrease in pulmonary arterial compliance, and increase in pulmonary vascular resistance. The symptoms of PAH are nonspecific, which often contributes to diagnostic challenges and significant delays in establishing the diagnosis. The investigation of PAH is extensive and involves thorough search for potential clinical conditions that may contribute to its development, as well as the exclusion of other causes of pulmonary hypertension. The proper hemodynamic definition of PAH requires right heart catheterization (RHC) and direct measurements of mean pulmonary artery pressure, pulmonary arterial wedge pressure, cardiac output, and pulmonary vascular resistance. Additionally, RHC allows the assessment of the severity of the disease and, in selected cases, the identification of patients with a positive pulmonary vascular vasoreactivity test. RHC also provides valuable longitudinal information for risk stratification and patient follow-up. In the current manuscript, we review the PAH diagnostic workup, including a detailed review of the most up-to-date recommendations for right RHC and patient risk stratification.
- 11 December 2025
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 51 (6) , e20250065
Open AccessDiagnosis of pulmonary arterial hypertension: a statement from the Brazilian Thoracic Association
Pulmonary arterial hypertension (PAH) is a condition that predominantly affects the pulmonary arterial bed, leading to pulmonary vascular remodeling, progressive decrease in pulmonary arterial compliance, and increase in pulmonary vascular resistance. The symptoms of PAH are nonspecific, which often contributes to diagnostic challenges and significant delays in establishing the diagnosis. The investigation of PAH is extensive and involves thorough search for potential clinical conditions that may contribute to its development, as well as the exclusion of other causes of pulmonary hypertension. The proper hemodynamic definition of PAH requires right heart catheterization (RHC) and direct measurements of mean pulmonary artery pressure, pulmonary arterial wedge pressure, cardiac output, and pulmonary vascular resistance. Additionally, RHC allows the assessment of the severity of the disease and, in selected cases, the identification of patients with a positive pulmonary vascular vasoreactivity test. RHC also provides valuable longitudinal information for risk stratification and patient follow-up. In the current manuscript, we review the PAH diagnostic workup, including a detailed review of the most up-to-date recommendations for right RHC and patient risk stratification.
- Open Access
- 9 November 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Unveiling orthostatic hypotension in precapillary pulmonary hypertension
Background: In addition to critical alterations in the pulmonary arterial network, pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) may exhibit cardiovascular abnormalities that impair systemic arterial pressure regulation during gravitational challenges. Therefore, we investigated the prevalence, subtypes and haemodynamic mechanisms of orthostatic hypotension (OH) in PAH or CTEPH. Methods: OH was assessed using a 10-min active standing manoeuvre from supine baseline, with heart rate (HR; ECG) and arterial pressure (volume-clamp finger photoplethysmography) measured beat by beat. Stroke volume (SV) was estimated from the arterial pressure waveform, and cardiac output (CO) and total peripheral resistance (TPR) were calculated. Results: Among 60 patients, 31 (52%) had OH. Patients with and without OH did not differ in clinical characteristics and OH related symptoms (all p>0.050). HR, SV, CO and TPR responses (% change from supine baseline) were not different between groups with and without initial OH (p>0.05). However, SV decrease was greater in the group with than without delayed arterial pressure recovery (−31±21 versus −19±14%; p=0.033). Additionally, a compensatory increase in TPR was blunted in the group with classic/delayed OH compared with without OH (−6±21 versus 7±15%; p=0.023). Conclusion: OH is common in patients with PAH or CTEPH but is not associated with specific clinical characteristics. Initial OH lacks a clear haemodynamic cause, whereas delayed recovery and classic/delayed OH are linked to impaired SV and TPR responses to standing, respectively.
- 9 November 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Open AccessUnveiling orthostatic hypotension in precapillary pulmonary hypertension
Background: In addition to critical alterations in the pulmonary arterial network, pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) may exhibit cardiovascular abnormalities that impair systemic arterial pressure regulation during gravitational challenges. Therefore, we investigated the prevalence, subtypes and haemodynamic mechanisms of orthostatic hypotension (OH) in PAH or CTEPH. Methods: OH was assessed using a 10-min active standing manoeuvre from supine baseline, with heart rate (HR; ECG) and arterial pressure (volume-clamp finger photoplethysmography) measured beat by beat. Stroke volume (SV) was estimated from the arterial pressure waveform, and cardiac output (CO) and total peripheral resistance (TPR) were calculated. Results: Among 60 patients, 31 (52%) had OH. Patients with and without OH did not differ in clinical characteristics and OH related symptoms (all p>0.050). HR, SV, CO and TPR responses (% change from supine baseline) were not different between groups with and without initial OH (p>0.05). However, SV decrease was greater in the group with than without delayed arterial pressure recovery (−31±21 versus −19±14%; p=0.033). Additionally, a compensatory increase in TPR was blunted in the group with classic/delayed OH compared with without OH (−6±21 versus 7±15%; p=0.023). Conclusion: OH is common in patients with PAH or CTEPH but is not associated with specific clinical characteristics. Initial OH lacks a clear haemodynamic cause, whereas delayed recovery and classic/delayed OH are linked to impaired SV and TPR responses to standing, respectively.
- 16 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2501206
Oxygen pulse plateau as a qualitative marker for risk stratification in PAH
- 16 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2501206
Oxygen pulse plateau as a qualitative marker for risk stratification in PAH
- 23 September 2025
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 339, 104490
Gas exchange dynamics and responses to exercise in chronic thromboembolic pulmonary hypertension
- 23 September 2025
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 339, 104490
Gas exchange dynamics and responses to exercise in chronic thromboembolic pulmonary hypertension
- Open Access
- 11 September 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Long-term effects of medical treatment in patients with chronic thromboembolic pulmonary hypertension
Background: The New International Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry, conducted between 2015 and 2019, revealed the significant impact of pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) on the long-term survival of CTEPH patients. The objective of the current pre-specified analysis was to evaluate the effect of medical treatment, including the approved oral guanylate cyclase stimulator (sGC) riociguat, in patients with or without mechanical intervention. Methods: 1009 newly diagnosed patients were included in the study, with recruitment conducted at 34 centres across 20 countries. At the outset of the registry, sGC was available in 85% of the countries involved. Results: 52% of all patients included were treated with pulmonary hypertension (PH) drugs. The proportion of patients receiving PH drugs was 38% among the 605 patients who underwent PEA, 78% among the 185 patients who underwent BPA and 76% among the 219 remaining patients who did not undergo PEA or BPA. In the “BPA” and “no PEA/BPA” groups, the 3-year survival was superior in patients who received sGC in comparison with other PH drugs. Cox regression confirmed that sGC treatment was associated with reduced mortality in the global cohort, in the BPA group and in the “no PEA/BPA” group. Conclusion: This international CTEPH registry suggests that, although an increasing proportion of patients with CTEPH benefited from mechanical treatment, medical treatment with sGC may be associated with a survival advantage in patients undergoing BPA or no intervention. These observations confirm the results of previous randomised controlled trials in a real-world setting.
- 11 September 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessLong-term effects of medical treatment in patients with chronic thromboembolic pulmonary hypertension
Background: The New International Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry, conducted between 2015 and 2019, revealed the significant impact of pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) on the long-term survival of CTEPH patients. The objective of the current pre-specified analysis was to evaluate the effect of medical treatment, including the approved oral guanylate cyclase stimulator (sGC) riociguat, in patients with or without mechanical intervention. Methods: 1009 newly diagnosed patients were included in the study, with recruitment conducted at 34 centres across 20 countries. At the outset of the registry, sGC was available in 85% of the countries involved. Results: 52% of all patients included were treated with pulmonary hypertension (PH) drugs. The proportion of patients receiving PH drugs was 38% among the 605 patients who underwent PEA, 78% among the 185 patients who underwent BPA and 76% among the 219 remaining patients who did not undergo PEA or BPA. In the “BPA” and “no PEA/BPA” groups, the 3-year survival was superior in patients who received sGC in comparison with other PH drugs. Cox regression confirmed that sGC treatment was associated with reduced mortality in the global cohort, in the BPA group and in the “no PEA/BPA” group. Conclusion: This international CTEPH registry suggests that, although an increasing proportion of patients with CTEPH benefited from mechanical treatment, medical treatment with sGC may be associated with a survival advantage in patients undergoing BPA or no intervention. These observations confirm the results of previous randomised controlled trials in a real-world setting.
- Open Access
- 1 July 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (3) , e70140
Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies
This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes to Week 24 were evaluated in patients with and without a favorable response to riociguat in two trials: RESPITE, in which patients with an inadequate response to PDE5i were switched to riociguat; and REPLACE, in which patients at intermediate risk of 1‐year mortality despite a PDE5i were randomized to remain on PDE5i or were switched to riociguat. A response was defined as absence of clinical worsening and at least two of the following criteria: 6‐min walk distance increase by 10% or ≥ 30 m, World Health Organization functional class I/II, or N‐terminal prohormone of brain natriuretic peptide reduction of ≥ 30% at Week 24. In REPLACE, responders had significantly higher baseline cyclic guanosine monophosphate (cGMP) and significantly lower baseline asymmetric dimethylarginine, and growth/differentiation factor 15 (GDF‐15) than nonresponders. In RESPITE, responders had lower baseline GDF‐15 than nonresponders, and nonresponders showed a significantly greater decrease in cGMP than responders. No baseline threshold value of any biomarker provided a good likelihood of predicting the response to riociguat. Overall, the biomarkers evaluated did not help to identify patients who were more likely to respond to switching from PDE5is to riociguat.
- 1 July 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (3) , e70140
Open AccessPredicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies
This exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension. Selected biomarkers at baseline and their changes to Week 24 were evaluated in patients with and without a favorable response to riociguat in two trials: RESPITE, in which patients with an inadequate response to PDE5i were switched to riociguat; and REPLACE, in which patients at intermediate risk of 1‐year mortality despite a PDE5i were randomized to remain on PDE5i or were switched to riociguat. A response was defined as absence of clinical worsening and at least two of the following criteria: 6‐min walk distance increase by 10% or ≥ 30 m, World Health Organization functional class I/II, or N‐terminal prohormone of brain natriuretic peptide reduction of ≥ 30% at Week 24. In REPLACE, responders had significantly higher baseline cyclic guanosine monophosphate (cGMP) and significantly lower baseline asymmetric dimethylarginine, and growth/differentiation factor 15 (GDF‐15) than nonresponders. In RESPITE, responders had lower baseline GDF‐15 than nonresponders, and nonresponders showed a significantly greater decrease in cGMP than responders. No baseline threshold value of any biomarker provided a good likelihood of predicting the response to riociguat. Overall, the biomarkers evaluated did not help to identify patients who were more likely to respond to switching from PDE5is to riociguat.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14960
Tracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery
A hallmark of COVID-19 patients is the reduction of the lymphocyte population accompanied by activation, senescence, and exhaustion markers. We investigated patients admitted to hospital wards who either recovered after a short hospitalization or progressed to critical illness. Patients (n=48) were recruited between May and September 2020; 19 healthy volunteers were enrolled as controls. Blood samples were collected on days 0, 3, and 7 of hospitalization and around 30 days after discharge (convalescence sample, CS30). Lymphocyte counts and extended immunophenotyping were performed by flow cytometry and analyzed using conventional and stochastic methods. At D0 and D7, total lymphocytes, natural killer cells, T cells, TCD4 cells, and TCD8 cells were lower in patients than in volunteers but were restored at CS30. The stochastic analysis identified 11 distinct clusters of lymphocytes, nine of them with significant differences between patients and healthy controls. Clusters of TCD8+ memory cells showing activation, senescence, and exhaustion were increased in patients during hospitalization and in the convalescence samples. In contrast, clusters 5 (TCD4+ Central Memory exhausted activated) and 7 (TCD4+ Central Memory exhausted) were decreased in patients during the disease compared to healthy controls. Overall, the conventional flow cytometry analyses corroborated the findings from the stochastic analysis, showing that effector memory (EM) and TEMRA subsets exhibited sustained markers of exhaustion and senescence, particularly in TCD8+ cells. Our findings reinforce lymphopenia, T cell activation, senescence, and exhaustion as essential immunological features of COVID-19; while cell counts fully recovered, lymphocytes remained dysfunctional in convalescent samples.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14960
Open AccessTracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery
A hallmark of COVID-19 patients is the reduction of the lymphocyte population accompanied by activation, senescence, and exhaustion markers. We investigated patients admitted to hospital wards who either recovered after a short hospitalization or progressed to critical illness. Patients (n=48) were recruited between May and September 2020; 19 healthy volunteers were enrolled as controls. Blood samples were collected on days 0, 3, and 7 of hospitalization and around 30 days after discharge (convalescence sample, CS30). Lymphocyte counts and extended immunophenotyping were performed by flow cytometry and analyzed using conventional and stochastic methods. At D0 and D7, total lymphocytes, natural killer cells, T cells, TCD4 cells, and TCD8 cells were lower in patients than in volunteers but were restored at CS30. The stochastic analysis identified 11 distinct clusters of lymphocytes, nine of them with significant differences between patients and healthy controls. Clusters of TCD8+ memory cells showing activation, senescence, and exhaustion were increased in patients during hospitalization and in the convalescence samples. In contrast, clusters 5 (TCD4+ Central Memory exhausted activated) and 7 (TCD4+ Central Memory exhausted) were decreased in patients during the disease compared to healthy controls. Overall, the conventional flow cytometry analyses corroborated the findings from the stochastic analysis, showing that effector memory (EM) and TEMRA subsets exhibited sustained markers of exhaustion and senescence, particularly in TCD8+ cells. Our findings reinforce lymphopenia, T cell activation, senescence, and exhaustion as essential immunological features of COVID-19; while cell counts fully recovered, lymphocytes remained dysfunctional in convalescent samples.
- Top Cited PapersOpen Access
- 22 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (17) , 1354-1365
Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context. METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019. RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Of patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes.s.cm −5 . During the observation period (>3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention ( P P =0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention. CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02656238.
- 22 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (17) , 1354-1365
Top Cited PapersOpen AccessWorldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context. METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019. RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Of patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes.s.cm −5 . During the observation period (>3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention ( P P =0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention. CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02656238.